|
Our Products
Vyteris' first product, LidoSite®, which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA-approved active patch. Vyteris has now entered into an agreement with Ferring Pharmaceuticals, Inc., a leading innovator in the field of naturally-occurring human peptides, regarding the licensing and marketing of a female infertility therapy product based on Vyteris' active patch technology delivering a fertility enhancement peptide.
Vyteris has also successfully demonstrated in-vivo, either in animals or in humans, the ability of their active patch technology to deliver drugs transdermally for the following applications: smoking cessation, anti-aging cosmeceuticals, treatments for Parkinson's disease, and peptides for various indications.
LidoSite®
Read more About LidoSite®, including what it is and how it works, and watch a video about how LidoSite® has positively impacted pain management.
Learn about New Developments and Clinical Trials involving Vyteris’ active patch system. |
